At the forefront of research, development, commercialization of innovative, and potential     best-in-class total solutions for valvular heart diseases

 

3
2022.05

MicroPort CardioFlow’s Strategic Partner 4C Medical Technologies Completed Multiple TMVR Procedures with AltaValve™ Using the Next Generation Low Profile Fully Retrievable Transseptal Delivery System

The procedures were performed by Dr. Vlasis Ninios, Director of Department of Cardiology at the Interbalken Medical Center in Thessaloniki, Greece.

31
2022.03

CardioFlow Medtech Announces Annual Results for 2021

Shanghai, China, 29 March 2022 - MicroPort CardioFlow today announced the annual results of the Company and its subsidiaries for the 12 months ended December 31, 2021. In the Reporting Period, MicroPort CardioFlow recorded revenue of RMB200.8 million, representing a year-on-year growth of 93.2%. In addition to the significant growth in revenue, the gross profit margin also improved drastically by 15.4 percentage points to 59.1%.

8
2022.03

CardioFlow Medtech Receives Approval for Alwide® Plus Balloon Catheter in Argentina

Shanghai, China- MicroPort CardioFlow recently announced that the their Alwide® Plus Balloon Catheter has received marketing approval from the Argentine National Administration of Drugs, Foods, and Medical Devices (ANMAT).

7
2022.01

VitaFlow Liberty™ by MicroPort CardioFlow Obtains Approval in Argentina

MicroPort CardioFlow recently announced that its transcatheter aortic valve implantation (TAVI) solution, the new-generation VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™) has received marketing approval by the Argentine National Administration of Drugs, Foods, and Medical Devices (ANMAT).

28
2021.12

MicroPort CardioFlow has completed the submission of applications materials of VitaFlow Liberty™ for the EU CE certification

Shanghai, China, 28 December 2021 — MicroPort CardioFlow recently announced that its latest TAVI solution, the new-generation VitaFlow Liberty™ has completed the submission of applications materials for the EU CE certification

5
2021.11

MicroPort CardioFlow Participates in the 32nd GW-ICC, Drawing Expert Attention on Clinical Application of Motorized Retrievable Valve System

MicroPort CardioFlow hosted a symposium for its next-generation transcatheter aortic valve implantation (TAVI) product, the VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System, during the 32nd Great Wall International Congress of Cardiology (GW-ICC) and Asia Heart Society Congress. The event brought together experts in the field of structural heart disease to share their experience on the clinical application of VitaFlow Liberty™.